Tech Company Financing Transactions
Alchemab Therapeutics Funding Round
On 7/10/2026, Alchemab Therapeutics landed $34 million in Series A funding from Camford Capital, DCVC Bio and Dementia Discovery Fund.
Transaction Overview
Company Name
Announced On
7/10/2026
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to build its clinical pipeline and grow its proprietary antibody dataset to more than a billion sequences.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
London, Undisclosed
UK
London, Undisclosed
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires. The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jane Osbourn
Browse more venture capital transactions:
Prev: 7/10/2026: Hephae Energy Technology venture capital transaction
Next: 7/10/2026: Mercado Bitcoin venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs